TFF Pharmaceuticals announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Mikhak will be responsible for the clinical development of the company’s pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder clinical programs. "We are pleased to welcome Dr. Mikhak to TFF Pharmaceuticals as our Chief Medical Officer," said Dr. Harlan Weisman, Interim CEO of TFF Pharmaceuticals. "Dr. Mikhak brings to TFF an extraordinary depth of industry and clinical experience that will be instrumental in helping us advance our clinical-stage pipeline candidates and expand our pipeline. This appointment also signals the natural evolution of our Company, as we seek to further expand the clinical applications of Thin Film Freezing to help realize the full potential of our technology platform." Mikhak most recently served as Senior Vice President, Head of Clinical Development for Cogent Biosciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TFFP:
- TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
- TFF Pharmaceuticals Announces Leadership Transition
- TFF Pharmaceuticals announces CEO Glenn Mattes to step down
- TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering
- TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants